IP Library Granted Patent US 8,791,080
Granted Patent B2
US 8,791,080 · App. 13/125,551 · Granted Jul 29, 2014

Methods for treating gastrointestinal diseases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,791,080
App. No.
13/125,551
Granted
Jul 29, 2014
Kind
B2
Abstract

Described herein are macrolide and ketolide antibiotics and pharmaceutical compositions, methods, and uses thereof for treating gastrointestinal diseases.

Claims (11)

1. A method for treating a gastrointestinal disease caused by a bacteria in a host animal, the method comprising the step of administering to the host animal an effective amount of a compound of the formula

or pharmaceutically acceptable salt thereof;

or an antibacterial composition thereof further comprising one or more pharmaceutically acceptable carriers, excipients, or diluents therefor, or a combination thereof.

2. A method for treating a gastrointestinal disease caused by a bacteria in a host animal, the method comprising the step of administering an effective amount of the compound recited in claim 1 , or an antibacterial composition thereof further comprising one or more pharmaceutically acceptable carriers, excipients, or diluents therefor, or a combination thereof, wherein the effective amount is capable of killing the bacteria.

3. The method of claim 1 wherein the gastrointestinal disease is enteritis or gastroenteritis, or a combination thereof.

4. The method of claim 1 wherein the gastrointestinal disease is caused at least in part by an organism selected from the group consisting of Salmonella, Shigella, Staphylococcus, Campylobacter, Helicobacter, Clostridium, Escherichia coli , and Yersinia , and combinations thereof.

5. The method of claim 1 wherein the gastrointestinal disease is caused at least in part by H. pylori, C. jejuni, Salmonella, Shigella , or a combination thereof.

6. The method of claim 1 wherein the compound recited in claim 1 is of the formula

7. The method of claim 1 wherein the compound recited in claim 1 is of the formula

where HX is a pharmaceutically acceptable salt forming acid.

8. The method of claim 7 wherein HX is selected from the group consisting of hydrochloric acid, tartaric acid, and combinations thereof.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2019
From: CEMPRA PHARMACEUTICALS, INC.
To: TETARD, INC.
Reel/Frame 050056/0731 →
RELEASE OF SECURITY INTEREST Recorded Jun 4, 2019
From: CORTLAND CAPITAL MARKET SERVICES LLC
To: CEMPRA PHARMACEUTICALS, INC.
Reel/Frame 049363/0706 →
SECURITY INTEREST Recorded Jan 8, 2018
From: MELINTA THERAPEUTICS, INC.; REMPEX PHARMACEUTICALS, INC.; CEMPRA PHARMACEUTICALS, INC.; CEM-102 PHARMACEUTICALS, INC.
To: CORTLAND CAPITAL MARKET SERVICES LLC, AS AGENT
Reel/Frame 045019/0552 →